Table 1.
Clinical trials regarding circulating tumor cells in lung cancer.
| Name/NTC | Status | Condition/Patients (n) | Brief Summary |
|---|---|---|---|
| Development of Circulating Tumor Cell Molecular Diagnostics Using a Novel Microfluidic Device NCT01193829 |
Completed (2014) |
NSCLC n = 30 |
To compare EGFR mutations between NSCLC and corresponding CTCs isolated by a label-free microfluidic device-based system. The device was tested for the feasibility to detect clinically relevant EGFR mutations in CTCs. |
| Detecting EGFR T790M Mutations from Circulating Tumor Cells NCT01734915 |
Completed (2016) |
NSCLC with EGFR mutation n = 40 |
To determine whether the EGFR mutation can be detected in CTCs and if it reliably compares to tissue biopsy results. The CTC-chip was applied to isolate CTCs and identify the EGFR mutation in a less invasive way, aiming at facilitating the diagnosis of lung cancer. |
| A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System NCT02370303 |
Completed (2018) |
Stage IV LCa Stage IB or higher NSCLC n = 23 |
To isolate and quantify CTCs of lung cancer patients using the ClearCell® FX EP+ System, to advance cancer detection and treatment monitoring. For this, both blood and tumor samples were evaluated. Additionally, postoperative CTCs levels were assessed. |
| PDL-1 Expression on Circulating Tumor Cells in Non-small Cell Lung Cancer (IMMUNO-PREDICT) NCT02827344 |
Recruiting | Stage IV NSCLC n= 200 |
To demonstrate the feasibility of the analysis of PD-L1 expression on CTCs isolated by ISET filtration module. |
| Circulating Tumor Cells in Lung Cancer Screening (AIR) NCT02500693 |
Unknown | High-risk patients n = 600 |
To evaluate the predictive value of CTC detection for the diagnosis of lung cancer with the ISET technology. |
| Circulating Tumor Cells Spillage After Pulmonary Biopsy NCT02507778 |
Unknown | LCa n = 40 |
To quantify the number of CTCs and correlate with the tumor response to chemotherapy. Here, the CellCollectorTM, which detects and isolates EpCAM+ CTCs is applied. |
| Application of Detecting Circulating Tumor Cells in the Accurate Treatment of Early Stage Lung Adenocarcinoma (CTCs detection) NCT02951897 |
Unknown | Stage I Adenocarcinoma n = 120 |
To explore whether CTCs detection in patients diagnosed with early-stage lung cancer, and prior to surgery, can aid with early diagnosis or contribute to predict the prognosis and treatment strategies. The CanPatrolTM technology is applied for CTCs enrichment. |
| The Method ISET (Insulation by Size of Epithelial Tumor Cells) NCT00818558 |
Unknown | NSCLC n = 520 |
To evaluate the potential of ISET method to preoperative detection of CTC in patients with NSCLC. Furthermore, to correlate the presence of CTCs with pTNM stage, histology, and primary tumor cellularity. |
Information collected from www.clinicatrials.gov, accessed on 5 January 2021. Abbreviations: LCa—lung cancer; NSCLC—non-small cell lung cancer; EGFR—epidermal growth factor receptor; CTCs—circulating tumor cells; ISET—isolation by size of epithelial tumor cells; pTNM—pathological tumor-node-metastasis; cfDNA—circulating cell-free DNA.